Capital Impact Advisors LLC grew its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Rating) by 9.9% in the third quarter, Holdings Channel reports. The fund owned 17,673 shares of the medical instruments supplier’s stock after acquiring an additional 1,599 shares during the quarter. LeMaitre Vascular accounts for 0.8% of Capital Impact Advisors LLC’s portfolio, making the stock its 25th largest holding. Capital Impact Advisors LLC’s holdings in LeMaitre Vascular were worth $798,000 as of its most recent filing with the SEC.
A number of other large investors also recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of LeMaitre Vascular by 0.8% in the 3rd quarter. BlackRock Inc. now owns 3,267,883 shares of the medical instruments supplier’s stock valued at $165,616,000 after acquiring an additional 26,787 shares during the last quarter. Vanguard Group Inc. increased its holdings in LeMaitre Vascular by 10.1% in the first quarter. Vanguard Group Inc. now owns 1,426,235 shares of the medical instruments supplier’s stock valued at $66,278,000 after purchasing an additional 130,881 shares during the period. Copeland Capital Management LLC increased its holdings in LeMaitre Vascular by 0.9% in the third quarter. Copeland Capital Management LLC now owns 1,223,582 shares of the medical instruments supplier’s stock valued at $62,011,000 after purchasing an additional 11,276 shares during the period. Geneva Capital Management LLC increased its holdings in LeMaitre Vascular by 4.1% in the third quarter. Geneva Capital Management LLC now owns 891,838 shares of the medical instruments supplier’s stock valued at $45,199,000 after purchasing an additional 35,059 shares during the period. Finally, State Street Corp increased its holdings in LeMaitre Vascular by 6.2% in the second quarter. State Street Corp now owns 754,066 shares of the medical instruments supplier’s stock valued at $34,348,000 after purchasing an additional 44,301 shares during the period. 86.85% of the stock is currently owned by institutional investors.
LeMaitre Vascular Trading Up 1.5 %
Shares of LeMaitre Vascular stock opened at $50.56 on Friday. The business has a 50-day moving average price of $48.23 and a two-hundred day moving average price of $47.80. LeMaitre Vascular, Inc. has a 1-year low of $38.32 and a 1-year high of $56.38. The company has a market cap of $1.12 billion, a P/E ratio of 54.37, a PEG ratio of 4.12 and a beta of 0.98.
LeMaitre Vascular Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 23rd. Shareholders of record on Thursday, March 9th will be issued a dividend of $0.14 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.13. This represents a $0.56 dividend on an annualized basis and a yield of 1.11%. The ex-dividend date of this dividend is Wednesday, March 8th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 60.22%.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the company. Roth Capital restated a “neutral” rating on shares of LeMaitre Vascular in a report on Tuesday, March 7th. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, March 10th.
Insiders Place Their Bets
In other news, insider Trent G. Kamke sold 6,414 shares of the firm’s stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $50.94, for a total value of $326,729.16. Following the completion of the sale, the insider now directly owns 3,791 shares in the company, valued at approximately $193,113.54. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 12.50% of the company’s stock.
LeMaitre Vascular Profile
LeMaitre Vascular, Inc engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy.
- Get a free copy of the StockNews.com research report on LeMaitre Vascular (LMAT)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Rating).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.